Siegfried has acquired Purisys, a global leader in custom synthesis of active pharmaceutical ingredients (APIs), for an undisclosed amount. Purisys supports pharmaceutical and biotech companies with APIs, reference standards, controlled substances, cannabinoids, psychedelics, and cGMP clinical and niche commercial CDMO services. The company, which began manufacturing in 1979 as part of Johnson & Johnson before spinning off from Noramco in 2019, holds a significant position in specialized API development.
Purisys is particularly recognized for its expertise in pharmaceutical cannabinoids and psychedelics, producing over 50 major and minor cannabinoids, as well as GMP psilocybin and psilocin for R&D programs. Its capabilities extend to custom API and drug development and manufacturing (CDMO) services, handling difficult-to-manufacture APIs, and offering a comprehensive catalog of over 250 in-stock reference standards shipped globally.
This acquisition is strategically significant for Siegfried, enhancing its portfolio with Purisys's specialized capabilities in emerging therapeutic areas like cannabinoids and psychedelics. The purchase allows Siegfried to integrate Purisys's advanced custom synthesis and CDMO services, expanding its offering to clients seeking preclinical-to-commercial APIs, including controlled substances and high-potency compounds. The synergy is expected to broaden market reach and deepen expertise in complex API manufacturing.
The combination of Siegfried's existing operations with Purisys's established history and specialized knowledge is anticipated to create a more comprehensive service provider in the pharmaceutical contract development and manufacturing sector. The unified entity aims to better serve the evolving needs of the global pharmaceutical and biotech industries, particularly in niche and high-growth therapeutic segments.